Last reviewed · How we verify
batch 3 of MCV4
MCV4 is a vaccine that stimulates the body's immune response to the meningococcal conjugate serogroups A, C, W, and Y.
MCV4 is a vaccine that stimulates the body's immune response to the meningococcal conjugate serogroups A, C, W, and Y. Used for Active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 months through 55 years of age..
At a glance
| Generic name | batch 3 of MCV4 |
|---|---|
| Also known as | Menhycia |
| Sponsor | CanSino Biologics Inc. |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
MCV4 works by introducing a small, harmless piece of the meningococcal bacteria to the body, which triggers an immune response and helps the body produce antibodies to fight the infection. This immune response provides long-term protection against meningococcal disease.
Approved indications
- Active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 months through 55 years of age.
Common side effects
- Pain, redness, swelling, or itching at the injection site
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- batch 3 of MCV4 CI brief — competitive landscape report
- batch 3 of MCV4 updates RSS · CI watch RSS
- CanSino Biologics Inc. portfolio CI